

Carlo Gambacorti-Passerini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/506457/publications.pdf>

Version: 2024-02-01

242
papers

18,881
citations

20817

60
h-index

12946

131
g-index

245
all docs

245
docs citations

245
times ranked

18188
citing authors

#	ARTICLE	IF	CITATIONS
1	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2022, 6, 327-338.	5.2	28
2	Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. <i>Blood</i> , 2022, 139, 717-731.	1.4	22
3	Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success. <i>American Journal of Hematology</i> , 2022, 97, 1075-1085.	4.1	13
4	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. <i>Blood Reviews</i> , 2022, 56, 100968.	5.7	16
5	Can Similarities between the Pathogenesis of Preeclampsia and COVID-19 Increase the Understanding of COVID-19?. <i>International Journal of Translational Medicine</i> , 2022, 2, 186-197.	0.4	3
6	Discovery of Novel \pm -Carboline Inhibitors of the Anaplastic Lymphoma Kinase. <i>ACS Omega</i> , 2022, 7, 17083-17097.	3.5	7
7	Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	2
8	Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. <i>Leukemia</i> , 2022, 36, 1825-1833.	7.2	43
9	Identification of non-ATP-competitive \pm -carboline inhibitors of the anaplastic lymphoma kinase. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114488.	5.5	3
10	Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. <i>Haematologica</i> , 2021, 106, 1693-1704.	3.5	40
11	Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic phase CML in clinical practice: 3-year European SIMPLICITY data. <i>European Journal of Haematology</i> , 2021, 106, 82-89.	2.2	14
12	STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2021, 35, 1500-1505.	7.2	29
13	Impact of <i>ETNK1</i> somatic mutations on phosphoethanolamine synthesis, ROS production and DNA damage. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1877598.	0.7	3
14	Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. <i>Mayo Clinic Proceedings</i> , 2021, 96, 817.	3.0	1
15	VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples. <i>Patterns</i> , 2021, 2, 100212.	5.9	26
16	Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy. <i>European Journal of Haematology</i> , 2021, 106, 808-820.	2.2	10
17	Being a Myeloproliferative Patient in COVID-19 Era: The Mytico Study. <i>Frontiers in Oncology</i> , 2021, 11, 668261.	2.8	1
18	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103105.	1.0	3

#	ARTICLE	IF	CITATIONS
19	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021, 195, 371-377.	2.5	56
20	Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome-positive leukemias. <i>Leukemia Research</i> , 2021, 111, 106690.	0.8	12
21	Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma. <i>Cancers</i> , 2021, 13, 4422.	3.7	11
22	Letter to the Editor: sFlt-1 and PlGF Levels in Pregnancies Complicated by SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2377.	3.3	5
23	Risk of Progression in Chronic Phase - Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO study): Preliminary Results. <i>Blood</i> , 2021, 138, 1476-1476.	1.4	1
24	Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 756348.	2.8	5
25	An Update of Safety and Efficacy Results from Phase 1 Dose-Escalation and Expansion Study of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI), in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Failing Prior TKI Therapies. <i>Blood</i> , 2021, 138, 309-309.	1.4	3
26	An Imatinib-non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 71-74.	0.5	1
27	The role of bosutinib in the treatment of chronic myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 4395-4408.	2.4	26
28	ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. <i>Nature Communications</i> , 2020, 11, 5938.	12.8	22
29	A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. <i>Leukemia Research</i> , 2020, 97, 106441.	0.8	8
30	Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia. <i>HemaSphere</i> , 2020, 4, e497.	2.7	14
31	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	2.4	2
32	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	4.6	430
33	Pregnancy outcomes in patients treated with bosutinib. <i>International Journal of Hematologic Oncology</i> , 2020, 9, IJH26.	1.6	17
34	Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy. <i>American Journal of Hematology</i> , 2020, 95, E319-E321.	4.1	21
35	Increased sFlt-1/PlGF ratio in COVID-19: A novel link to angiotensin II-mediated endothelial dysfunction. <i>American Journal of Hematology</i> , 2020, 95, E188-E191.	4.1	51
36	IL13RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 1657-1669.	1.4	22

#	ARTICLE	IF	CITATIONS
37	Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. <i>Leukemia</i> , 2020, 34, 2125-2137.	7.2	47
38	Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation. <i>Blood</i> , 2020, 136, 2237-2240.	1.4	13
39	Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients. <i>Scientific Reports</i> , 2020, 10, 542.	3.3	4
40	Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1241-1249.	1.8	9
41	Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial. <i>Blood</i> , 2020, 136, 41-42.	1.4	27
42	Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib. <i>Blood</i> , 2020, 136, 51-52.	1.4	20
43	Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study. <i>Blood Research</i> , 2020, 55, 139-145.	1.3	2
44	Retro-Pro prospective Observational Study on the Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation (TFR-PRO). <i>Blood</i> , 2020, 136, 21-22.	1.4	0
45	Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial. <i>Blood</i> , 2020, 136, 34-35.	1.4	3
46	ETNK1 Mutations in Atypical Chronic Myeloid Leukemia Induce a Mutator Phenotype That Can be Reverted with Phosphoethanolamine. <i>Blood</i> , 2020, 136, LBA-5-LBA-5.	1.4	1
47	TREATMENT PATTERNS IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKAEMIA IN ROUTINE CLINICAL PRACTICE: THE SIMPLICITY ITALIAN POPULATION. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019025.	1.3	7
48	A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. <i>Journal of Thoracic Oncology</i> , 2019, 14, e257-e259.	1.1	23
49	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. <i>Leukemia</i> , 2019, 33, 1835-1850.	7.2	97
50	Acute myeloid leukaemia niche regulates response to L-asparaginase. <i>British Journal of Haematology</i> , 2019, 186, 420-430.	2.5	18
51	Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1589-1599.	2.5	21
52	De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways. <i>Haematologica</i> , 2019, 104, 1789-1797.	3.5	21
53	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	3.5	58
54	Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. <i>Current Medical Research and Opinion</i> , 2019, 35, 1615-1622.	1.9	13

#	ARTICLE	IF	CITATIONS
55	Wiskottâ€ Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 130-140.	30.7	57
56	Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronicâ€ phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2019, 94, 46-54.	4.1	32
57	Increased Tumour Burden over a 36 Month Period in Chronic Myeloid Leukemia Patients Following Imatinib Discontinuation: Role of Digital PCR. <i>Blood</i> , 2019, 134, 29-29.	1.4	2
58	Longâ€ term effects of crizotinib in ALKâ€ positive tumors (excluding NSCLC): A phase 1b openâ€ label study. <i>American Journal of Hematology</i> , 2018, 93, 607-614.	4.1	75
59	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. <i>Neoplasia</i> , 2018, 20, 467-477.	5.3	13
60	Î2-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: implications for a double-targeted therapy. <i>Oncogene</i> , 2018, 37, 3301-3316.	5.9	18
61	Ponatinib efficacy and safety in Philadelphia chromosomeâ€ positive leukemia: final 5-year results of the phase 2 PACE trial. <i>Blood</i> , 2018, 132, 393-404.	1.4	392
62	Longâ€ term patientâ€ reported outcomes from an openâ€ label safety and efficacy study of bosutinib in Philadelphia chromosomeâ€ positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. <i>Cancer</i> , 2018, 124, 587-595.	4.1	19
63	Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 231-237.	1.6	356
64	Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling. <i>Cancers</i> , 2018, 10, 509.	3.7	3
65	Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 143.	17.0	52
66	Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. <i>Cancer Research</i> , 2018, 78, 6866-6880.	0.9	69
67	Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. <i>Haematologica</i> , 2018, 103, 1298-1307.	3.5	49
68	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. <i>Cancers</i> , 2018, 10, 62.	3.7	73
69	SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. <i>Nature Communications</i> , 2018, 9, 2192.	12.8	66
70	Efficacy and Safety Following Dose Reduction of Bosutinib or Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia: Analysis of the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 3005-3005.	1.4	7
71	Pregnancy Outcomes in Patients Treated with Bosutinib. <i>Blood</i> , 2018, 132, 1729-1729.	1.4	6
72	Bosutinib or Imatinib in Older Vs Younger Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Phase 3 BFORE Trial. <i>Blood</i> , 2018, 132, 1734-1734.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. <i>Blood</i> , 2018, 132, 43-43.	1.4	10
74	The Transition from Childhood to Adulthood in Chronic Immune Thrombocytopenia Patients: Clinical Management and the Role of Splenectomy and Thrombopoietin Receptor Agonists in a Single Center Experience. <i>Blood</i> , 2018, 132, 4987-4987.	1.4	0
75	Retaining Parental Role Despite the Presence of Hematological Neoplastic Diseases: The Emanuela Project and the Role of the Hematologist. <i>Blood</i> , 2018, 132, 4752-4752.	1.4	0
76	OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes. <i>Scientific Reports</i> , 2017, 7, 46290.	3.3	31
77	Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 684-695.e6.	0.4	42
78	Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis. <i>European Journal of Cancer</i> , 2017, 77, 48-56.	2.8	74
79	How "precise" is precision medicine in hematology?. <i>Haematologica</i> , 2017, 102, 4-6.	3.5	7
80	Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients. <i>American Journal of Hematology</i> , 2017, 92, E623-E625.	4.1	13
81	First-line treatment selection and early monitoring patterns in chronic phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. <i>American Journal of Hematology</i> , 2017, 92, 1214-1223.	4.1	36
82	RET kinase inhibitors: a review of recent patents (2012-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 91-99.	5.0	19
83	The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition. <i>Journal of Cancer</i> , 2017, 8, 140-145.	2.5	12
84	Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update. <i>Blood</i> , 2017, 130, 900-900.	1.4	9
85	Bosutinib Vs Imatinib for Newly Diagnosed Chronic Myeloid Leukemia (CML) in the BFORE Trial: 18 Month Follow-up. <i>Blood</i> , 2017, 130, 896-896.	1.4	6
86	ALK inhibitors for clinical use in cancer therapy. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 46-60.	1.8	3
87	Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib. <i>American Journal of Hematology</i> , 2016, 91, 606-616.	4.1	76
88	Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2016, 9, 63.	17.0	18
89	Chronic myeloid leukemia: reminiscences and dreams. <i>Haematologica</i> , 2016, 101, 541-558.	3.5	92
90	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. <i>Blood</i> , 2016, 128, 774-782.	1.4	243

#	ARTICLE	IF	CITATIONS
91	Chronic myeloid leukemia: Secondâ€line drugs of choice. American Journal of Hematology, 2016, 91, 67-75.	4.1	33
92	Factors influencing longâ€term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib. British Journal of Haematology, 2016, 172, 97-110.	2.5	41
93	Longâ€term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. American Journal of Hematology, 2016, 91, 1206-1214.	4.1	90
94	Abrupt Relapse of <i>ALK</i>-Positive Lymphoma after Discontinuation of Crizotinib. New England Journal of Medicine, 2016, 374, 95-96.	27.0	67
95	Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene, 2016, 35, 3854-3865.	5.9	37
96	Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis. Blood, 2016, 128, 3075-3075.	1.4	1
97	Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Oncotarget, 2016, 7, 72886-72897.	1.8	25
98	Activity of secondâ€generation ALK inhibitors against crizotinibâ€resistant mutants in an NPMâ€ALK model compared to EML4â€ALK. Cancer Medicine, 2015, 4, 953-965.	2.8	72
99	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood, 2015, 125, 499-503.	1.4	115
100	Age and d<sc>PCR</sc> can predict relapse in <sc>CML</sc> patients who discontinued imatinib: The <sc>ISAV</sc> study. American Journal of Hematology, 2015, 90, 910-914.	4.1	181
101	RNAâ€seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients. American Journal of Hematology, 2015, 90, E227-8.	4.1	2
102	c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinaseâ€Activated Leukemias. Molecular Cancer Research, 2015, 13, 699-712.	3.4	55
103	Longâ€term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. American Journal of Hematology, 2015, 90, 755-768.	4.1	72
104	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	1.4	19
105	Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALKâ€Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research, 2015, 13, 775-783.	3.4	52
106	In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib. Journal of Hematology and Oncology, 2015, 8, 81.	17.0	20
107	BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Molecular Cancer, 2015, 14, 132.	19.2	35
108	Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients. Experimental Hematology, 2015, 43, 1015-1018.e1.	0.4	51

#	ARTICLE	IF	CITATIONS
109	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. <i>Leukemia Research</i> , 2015, 39, 1055-1059.	0.8	57
110	Imatinibâ€”A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. <i>JAMA Oncology</i> , 2015, 1, 143.	7.1	16
111	Bosutinib <i>versus</i> imatinib in newly diagnosed chronicâ€”phase chronic myeloid leukaemia: results from the 24â€”month followâ€”up of the BELA trial. <i>British Journal of Haematology</i> , 2015, 168, 69-81.	2.5	177
112	How <sc>l</sc> treat newly diagnosed chronic myeloid leukemia in 2015. <i>American Journal of Hematology</i> , 2015, 90, 156-161.	4.1	18
113	Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. <i>Journal of Clinical Investigation</i> , 2015, 125, 3505-3518.	8.2	32
114	NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. <i>Oncotarget</i> , 2015, 6, 5720-5734.	1.8	29
115	ETNK1 Is an Early Event and SETBP1 a Late Event in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3652-3652.	1.4	1
116	Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24â€”month followâ€”up. <i>American Journal of Hematology</i> , 2014, 89, 732-742.	4.1	102
117	Bosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 701-710.	1.8	16
118	Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinaseâ€”Positive Lymphoma Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt378.	6.3	207
119	Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 1303-1312.	3.0	20
120	Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. <i>Blood</i> , 2014, 123, 1309-1318.	1.4	124
121	Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2014, 89, 947-953.	4.1	98
122	Firstâ€”line treatment of 102 chronic myeloid leukemia patients with imatinib: A longâ€”term single institution analysis. <i>American Journal of Hematology</i> , 2014, 89, E184-7.	4.1	24
123	Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11â€”12, 2013. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 181-189.	4.4	5
124	Recurrent KIT D816V Mutation in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3576-3576.	1.4	1
125	The Risk of Relapse in CML Patients Who Discontinued imatinib Can Be Predicted Based on Patients Age and the Results of dPCR Analysis. <i>Blood</i> , 2014, 124, 813-813.	1.4	4
126	Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2212-2212.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. <i>Leukemia and Lymphoma</i> , 2013, 54, 1151-1158.	1.3	9
128	Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. <i>Molecular and Cellular Endocrinology</i> , 2013, 377, 1-6.	3.2	81
129	Clinical and biological implications of driver mutations in myelodysplastic syndromes. <i>Blood</i> , 2013, 122, 3616-3627.	1.4	1,562
130	Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. <i>Nature Genetics</i> , 2013, 45, 18-24.	21.4	359
131	Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex. <i>Neoplasia</i> , 2013, 15, 511-117.	5.3	44
132	A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 1291-1293.	7.3	1
133	Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. <i>Carcinogenesis</i> , 2013, 34, 2767-2773.	2.8	40
134	Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors. <i>Molecular Cancer Research</i> , 2013, 11, 122-132.	3.4	79
135	Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. <i>Molecular Genetics & Genomic Medicine</i> , 2013, 1, 246-259.	1.2	17
136	CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data. <i>PLoS ONE</i> , 2013, 8, e74825.	2.5	20
137	Bosutinib As Therapy For Chronic Phase Chronic Myeloid Leukemia Following Failure With Imatinib Plus Dasatinib and/Or Nilotinib: 36-Month Update. <i>Blood</i> , 2013, 122, 4025-4025.	1.4	1
138	FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery. <i>Nucleic Acids Research</i> , 2012, 40, e123-e123.	14.5	29
139	New developments in the treatment of ALK-driven malignancies. <i>Clinical Investigation</i> , 2012, 2, 835-852.	0.0	1
140	A Bioinformatics Procedure to Identify and Annotate Somatic Mutations in Whole-Exome Sequencing Data. <i>Lecture Notes in Computer Science</i> , 2012, , 73-82.	1.3	0
141	Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. <i>Blood</i> , 2012, 119, 3403-3412.	1.4	281
142	Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , 2012, 87, E125-8.	4.1	93
143	Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3486-3492.	1.6	404
144	Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e51449.	2.5	39

#	ARTICLE	IF	CITATIONS
145	Crizotinib in Anaplastic Large-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2011, 364, 775-776.	27.0	256
146	Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. <i>Experimental Hematology</i> , 2011, 39, 653-665.e6.	0.4	37
147	Choosing the right TKI for chronic myeloid leukemia: When the truth lies in "safety and efficacy. <i>American Journal of Hematology</i> , 2011, 86, 531-532.	4.1	8
148	Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors. <i>ChemMedChem</i> , 2011, 6, 1680-1692.	3.2	18
149	The ALK Gene, An Attractive Target for Inhibitor Development. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1406-1419.	2.1	12
150	Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome "positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. <i>Blood</i> , 2011, 118, 4567-4576.	1.4	406
151	Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 553-561.	6.3	362
152	Focal Adhesion Kinase (FAK) Binds RET Kinase via Its FERM Domain, Priming a Direct and Reciprocal RET-FAK Transactivation Mechanism. <i>Journal of Biological Chemistry</i> , 2011, 286, 17292-17302.	3.4	50
153	Activity of Bosutinib by Baseline and Emergent Mutation Status in Philadelphia Chromosome "Positive Leukemia Patients with Resistance or Intolerance to Other Tyrosine Kinase Inhibitors. <i>Blood</i> , 2011, 118, 110-110.	1.4	6
154	Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 1685-1685.	1.4	9
155	Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors. <i>Blood</i> , 2011, 118, 2760-2760.	1.4	2
156	Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts. <i>Blood</i> , 2011, 118, 3-3.	1.4	3
157	Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia " BELA Trial: 24-Month Follow-up. <i>Blood</i> , 2011, 118, 455-455.	1.4	9
158	ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells. <i>PLoS ONE</i> , 2011, 6, e28162.	2.5	25
159	Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. <i>Blood</i> , 2010, 116, 3013-3022.	1.4	110
160	Synthesis, structure " activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 1482-1496.	3.0	64
161	Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia. <i>Leukemia Research</i> , 2010, 34, e5-e7.	0.8	14
162	Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. <i>European Journal of Medicinal Chemistry</i> , 2010, 45, 2919-2927.	5.5	47

#	ARTICLE	IF	CITATIONS
163	BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. <i>Leukemia</i> , 2010, 24, 1445-1449.	7.2	37
164	Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib. <i>Leukemia</i> , 2010, 24, 1223-1227.	7.2	15
165	Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV. <i>Journal of Oncology</i> , 2010, 2010, 1-10.	1.3	36
166	Reply to P. Laneuville et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e172-e172.	1.6	7
167	Are Chronic Myeloid Leukemia Patients More at Risk for Second Malignancies? A Population-based Study. <i>American Journal of Epidemiology</i> , 2010, 172, 1028-1033.	3.4	39
168	Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL leukemia stem cells. <i>Nanomedicine</i> , 2010, 5, 419-431.	3.3	33
169	Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia. <i>European Journal of Cancer</i> , 2010, 46, 1781-1789.	2.8	62
170	Deregulated Activity and Localization of Glycogen Synthase Kinase 3 β In Chronic Myeloid Leukemia Progenitors: Role In Leukemia Maintenance and Targeted Therapy.. <i>Blood</i> , 2010, 116, 1216-1216.	1.4	0
171	Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.. <i>Journal of Biological Chemistry</i> , 2009, 284, 16060.	3.4	0
172	Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants. <i>Journal of Clinical Oncology</i> , 2009, 27, 469-471.	1.6	365
173	Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients. <i>Cancer Research</i> , 2009, 69, 7338-7346.	0.9	157
174	Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. <i>International Journal of Cancer</i> , 2009, 124, 1990-1996.	5.1	29
175	Part I: Milestones in personalised medicine—imatinib. <i>Lancet Oncology</i> , The, 2008, 9, 600.	10.7	51
176	BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells. <i>Molecular Cancer Research</i> , 2008, 6, 751-759.	3.4	178
177	A Mechanistic Design Principle for Protein Tyrosine Kinase Sensors: Application to a Validated Cancer Target. <i>Organic Letters</i> , 2008, 10, 301-304.	4.6	16
178	Characterization of Some Molecular Mechanisms Governing Autoactivation of the Catalytic Domain of the Anaplastic Lymphoma Kinase. <i>Journal of Biological Chemistry</i> , 2008, 283, 3743-3750.	3.4	61
179	Characterization of compound 584, an Abl kinase inhibitor with lasting effects. <i>Haematologica</i> , 2008, 93, 653-661.	3.5	14
180	Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. <i>Blood</i> , 2008, 111, 816-828.	1.4	44

#	ARTICLE	IF	CITATIONS
181	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon- α treatment. <i>Blood</i> , 2008, 111, 1039-1043.	1.4	195
182	Validation of PDGFR β and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. <i>Blood</i> , 2008, 112, 1346-1356.	1.4	99
183	Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. <i>Haematologica</i> , 2008, 93, 317-318.	3.5	32
184	Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting. <i>Journal of Biological Chemistry</i> , 2007, 282, 29230-29240.	3.4	90
185	Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2007, 7, 594-611.	1.7	27
186	NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. <i>Blood</i> , 2007, 110, 2600-2609.	1.4	34
187	The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome α -negative cells. <i>Cancer</i> , 2007, 110, 1509-1519.	4.1	121
188	In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. <i>Nature Medicine</i> , 2007, 13, 13-14.	30.7	54
189	Bcr-Abl stabilizes β -catenin in chronic myeloid leukemia through its tyrosine phosphorylation. <i>EMBO Journal</i> , 2007, 26, 1456-1466.	7.8	204
190	FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome α -positive acute lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2007, 117, 2408-2421.	8.2	308
191	Structural Insights into the ATP Binding Pocket of the Anaplastic Lymphoma Kinase by Site-Directed Mutagenesis, Inhibitor Binding Analysis, and Homology Modeling. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5759-5768.	6.4	33
192	The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 37, 111-115.	1.4	9
193	A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer. <i>International Journal of Biological Macromolecules</i> , 2006, 39, 60-65.	7.5	2
194	BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B. <i>Blood</i> , 2006, 107, 1591-1598.	1.4	53
195	Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient. <i>American Journal of Hematology</i> , 2006, 81, 646-646.	4.1	7
196	Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2006, 354, 2623-2624.	27.0	66
197	SKI-606 Decreases Growth and Motility of Colorectal Cancer Cells by Preventing pp60(c-Src) α -Dependent Tyrosine Phosphorylation of β -Catenin and Its Nuclear Signaling. <i>Cancer Research</i> , 2006, 66, 2279-2286.	0.9	117
198	In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells. <i>Cancer Research</i> , 2006, 66, 11314-11322.	0.9	352

#	ARTICLE	IF	CITATIONS
199	Inhibition of RET tyrosine kinase by SU5416. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 199-212.	2.5	68
200	Prognostic variables in patients with chronic myeloid leukemia treated with imatinib. <i>Haematologica</i> , 2006, 91, 145a.	3.5	1
201	Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. <i>Transfusion</i> , 2005, 45, 1214-1220.	1.6	14
202	Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib. <i>Leukemia</i> , 2005, 19, 132-134.	7.2	15
203	Imatinib dose increase up to 1200â€‰mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients. <i>Leukemia</i> , 2005, 19, 1985-1987.	7.2	9
204	Unique Substrate Specificity of Anaplastic Lymphoma Kinase (ALK):â€‰ Development of Phosphoacceptor Peptides for the Assay of ALK Activity. <i>Biochemistry</i> , 2005, 44, 8533-8542.	2.5	53
205	Expression, purification, and inhibition of human RET tyrosine kinase. <i>Protein Expression and Purification</i> , 2005, 41, 177-185.	1.3	30
206	Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib. <i>Haematologica</i> , 2005, 90, 434.	3.5	0
207	Development of c-Kit-expressing Small-Cell Lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1723-1724.	6.3	5
208	Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. <i>Blood</i> , 2004, 103, 2787-2794.	1.4	30
209	PNAs as novel cancer therapeutics. <i>International Journal of Peptide Research and Therapeutics</i> , 2003, 10, 297-308.	0.1	2
210	Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells. <i>Experimental Hematology</i> , 2003, 31, 309-315.	0.4	59
211	Gynaecomastia in men with chronic myeloid leukaemia after imatinib. <i>Lancet, The</i> , 2003, 361, 1954-1956.	13.7	88
212	Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. <i>Lancet Oncology, The</i> , 2003, 4, 75-85.	10.7	349
213	ALK a Novel Lymphoma-associated Tumor Antigen for Vaccination Strategies. <i>Leukemia and Lymphoma</i> , 2003, 44, 1675-1681.	1.3	23
214	Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. <i>Blood</i> , 2003, 102, 1933-1935.	1.4	16
215	Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2003, 9, 625-32.	7.0	159
216	hnRNP A1 Nucleocytoplasmic Shuttling Activity Is Required for Normal Myelopoiesis and BCR/ABL Leukemogenesis. <i>Molecular and Cellular Biology</i> , 2002, 22, 2255-2266.	2.3	115

#	ARTICLE	IF	CITATIONS
217	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937.	1.4	943
218	ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes. <i>Blood</i> , 2002, 99, 2100-2106.	1.4	89
219	Binding of imatinib by β -1-acid glycoprotein. <i>Blood</i> , 2002, 100, 367-369.	1.4	34
220	Determination of β -1 Acid Glycoprotein in Patients with Ph+ Chronic Myeloid Leukemia during the First 13 Weeks of Therapy with STI571. <i>Blood Cells, Molecules, and Diseases</i> , 2002, 28, 75-85.	1.4	52
221	Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 2002, 346, 645-652.	27.0	1,899
222	Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. <i>Cancer Letters</i> , 2002, 175, 17-25.	7.2	441
223	Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones. <i>Genes Chromosomes and Cancer</i> , 2002, 35, 261-270.	2.8	14
224	BCR-ABL suppresses C/EBP β expression through inhibitory action of hnRNP E2. <i>Nature Genetics</i> , 2002, 30, 48-58.	21.4	301
225	Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. <i>British Journal of Haematology</i> , 2001, 112, 972-974.	2.5	19
226	Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. <i>Blood</i> , 2000, 95, 1758-1766.	1.4	454
227	In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor. <i>Journal of the National Cancer Institute</i> , 1999, 91, 163-168.	6.3	341
228	In Vitro Transcriptional and Translational Block of the bcl-2 Gene Operated by Peptide Nucleic Acid. <i>Biochemical and Biophysical Research Communications</i> , 1999, 264, 537-543.	2.1	51
229	BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation. <i>British Journal of Haematology</i> , 1998, 103, 1109-1115.	2.5	9
230	Inhibition of the ABL Kinase Activity Blocks the Proliferation of BCR/ABL+Leukemic Cells and Induces Apoptosis. <i>Blood Cells, Molecules, and Diseases</i> , 1997, 23, 380-394.	1.4	273
231	Effects of 1,25-Dihydroxy Vitamin D3 on All-Trans Retinoic Acid Sensitive and Resistant Acute Promyelocytic Leukemia Cells. <i>Biochemical and Biophysical Research Communications</i> , 1996, 224, 50-56.	2.1	20
232	Acute Promyelocytic Leukaemia Cells Resistant to Retinoic Acid Show Further Perturbation of the RAR β Signal Transduction System. <i>Leukemia and Lymphoma</i> , 1995, 16, 289-295.	1.3	21
233	The Role of the Immune System in Anti-Tumour Responses. <i>Drugs and Aging</i> , 1995, 7, 266-277.	2.7	4
234	Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. <i>Cancer Immunology, Immunotherapy</i> , 1993, 36, 315-322.	4.2	57

#	ARTICLE	IF	CITATIONS
235	Immunogenicity of fusion proteins. International Journal of Clinical and Laboratory Research, 1993, 23, 186-191.	1.0	3
236	Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunology, Immunotherapy, 1992, 34, 241-251.	4.2	42
237	Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells. Cancer Immunology, Immunotherapy, 1989, 28, 67-73.	4.2	19
238	Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2 - activated lymphocytes (LAK). Cancer and Metastasis Reviews, 1988, 7, 335-345.	5.9	9
239	Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. Cancer Immunology, Immunotherapy, 1986, 21, 148-55.	4.2	27
240	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. Research in Clinic and Laboratory, 1986, 16, 1-20.	0.3	7
241	Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells. Cancer and Metastasis Reviews, 1985, 4, 7-26.	5.9	22
242	MONOCYTE PROCOAGULANT ACTIVITY IN HYPEREOSINOPHILIC SYNDROME. Lancet, The, 1983, 322, 460-461.	13.7	3